

Nicola Tinari

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1652799/publications.pdf>

Version: 2024-02-01

82
papers

3,978
citations

186265
28
h-index

118850
62
g-index

82
all docs

82
docs citations

82
times ranked

5789
citing authors

#	ARTICLE	IF	CITATIONS
1	Blood Circulating CD133+ Extracellular Vesicles Predict Clinical Outcomes in Patients with Metastatic Colorectal Cancer. <i>Cancers</i> , 2022, 14, 1357.	3.7	13
2	Pancytopenia During Osimertinib Treatment in a Patient with EGFR-Mutated Non-Small Cell Lung Cancer. <i>OncoTargets and Therapy</i> , 2022, Volume 15, 407-410.	2.0	3
3	Whole breast radiotherapy in cN0 early breast cancer patients with pathological sentinel lymph nodes (pN1mic, pN1a) without axillary dissection: preliminary results of the observational LISEN trial. <i>Strahlentherapie Und Onkologie</i> , 2022, 198, 612-621.	2.0	4
4	Phenotypic and Proteomic Analysis Identifies Hallmarks of Blood Circulating Extracellular Vesicles in NSCLC Responders to Immune Checkpoint Inhibitors. <i>Cancers</i> , 2021, 13, 585.	3.7	25
5	A perspective analysis: microRNAs, glucose metabolism, and drug resistance in colon cancer stem cells. <i>Cancer Gene Therapy</i> , 2021, , .	4.6	6
6	Exosomes as Pleiotropic Players in Pancreatic Cancer. <i>Biomedicines</i> , 2021, 9, 275.	3.2	14
7	Retroperitoneal extension of massive ulcerated testicular seminoma through the inguinal canal: A case report. <i>Archivio Italiano Di Urologia Andrologia</i> , 2021, 93, 64-67.	0.8	1
8	Tgf- β 21 transcriptionally promotes 90K expression: possible implications for cancer progression. <i>Cell Death Discovery</i> , 2021, 7, 86.	4.7	2
9	Cliniciansâ€™ Attitude to Doublet Plus Anti-EGFR Versus Triplet Plus Bevacizumab as First-line Treatment in Left-Sided RAS and BRAF Wild-Type Metastatic Colorectal Cancer Patients: A Multicenter, â€œReal-Lifeâ€œ, Case-Control Study. <i>Clinical Colorectal Cancer</i> , 2021, , .	2.3	8
10	Prognostic Relevance of Neutrophil to Lymphocyte Ratio (NLR) in Luminal Breast Cancer: A Retrospective Analysis in the Neoadjuvant Setting. <i>Cells</i> , 2021, 10, 1685.	4.1	15
11	The HSP90/R2TP assembly chaperone promotes cell proliferation in the intestinal epithelium. <i>Nature Communications</i> , 2021, 12, 4810.	12.8	7
12	Drug Repurposing, an Attractive Strategy in Pancreatic Cancer Treatment: Preclinical and Clinical Updates. <i>Cancers</i> , 2021, 13, 3946.	3.7	15
13	Distinct HR expression patterns significantly affect the clinical behavior of metastatic HER2+ breast cancer and degree of benefit from novel anti-HER2 agents in the real world setting. <i>International Journal of Cancer</i> , 2020, 146, 1917-1929.	5.1	4
14	The Role of Dysfunctional Adipose Tissue in Pancreatic Cancer: A Molecular Perspective. <i>Cancers</i> , 2020, 12, 1849.	3.7	20
15	Neoadjuvant Immune-Checkpoint Blockade in Triple-Negative Breast Cancer: Current Evidence and Literature-Based Meta-Analysis of Randomized Trials. <i>Cancers</i> , 2020, 12, 2497.	3.7	17
16	Evaluation of Second-Line Anti-VEGF after First-Line Anti-EGFR Based Therapy in RAS Wild-Type Metastatic Colorectal Cancer: The Multicenter â€œSLAVEâ€œ-Study. <i>Cancers</i> , 2020, 12, 1259.	3.7	19
17	<p></p>Alectinib Induced Regression of Renal and Hepatic Cysts Caused by Crizotinib</p>International Medical Case Reports Journal, 2020, Volume 13, 89-93.	0.8	1
18	Persistence and adherence to androgen deprivation therapy in men with prostate cancer: an administrative database study. <i>Minerva Urologica E Nefrologica = the Italian Journal of Urology and Nephrology</i> , 2020, 72, 615-621.	3.9	12

#	ARTICLE	IF	CITATIONS
19	Palliative radiotherapy in advanced cancer patients treated with immune-checkpoint inhibitors: The PRACTICE study. <i>Biomedical Reports</i> , 2020, 12, 59-67.	2.0	9
20	PLC-gamma-1 phosphorylation status is prognostic of metastatic risk in patients with early-stage Luminal-A and -B breast cancer subtypes. <i>BMC Cancer</i> , 2019, 19, 747.	2.6	22
21	Prognostic relevance of DNA damage and repair biomarkers in elderly patients with hormone-receptor-positive breast cancer treated with neoadjuvant hormone therapy: evidence from the real-world setting. <i>Therapeutic Advances in Medical Oncology</i> , 2019, 11, 175883591985319.	3.2	2
22	Impact of primary tumor location in patients with RAS wild-type metastatic colon cancer treated with first-line chemotherapy plus anti-EGFR or anti-VEGF monoclonal antibodies: a retrospective multicenter study. <i>Journal of Cancer</i> , 2019, 10, 5926-5934.	2.5	24
23	The Benzimidazole-Based Anthelmintic Parbendazole: A Repurposed Drug Candidate That Synergizes with Gemcitabine in Pancreatic Cancer. <i>Cancers</i> , 2019, 11, 2042.	3.7	36
24	Combination of peripheral neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio is predictive of pathological complete response after neoadjuvant chemotherapy in breast cancer patients. <i>Breast</i> , 2019, 44, 33-38.	2.2	109
25	Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial. <i>Lancet Oncology</i> , The, 2018, 19, 474-485.	10.7	59
26	Fabric phase sorptive extraction-high performance liquid chromatography-photo diode array detection method for simultaneous monitoring of three inflammatory bowel disease treatment drugs in whole blood, plasma and urine. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2018, 1084, 53-63.	2.3	55
27	Neoadjuvant chemotherapy in triple-negative breast cancer: A multicentric retrospective observational study in real-life setting. <i>Journal of Cellular Physiology</i> , 2018, 233, 2313-2323.	4.1	33
28	90K immunostimulatory glycoprotein in children with juvenile idiopathic arthritis. <i>Modern Rheumatology</i> , 2018, 28, 637-641.	1.8	5
29	Effects of repurposed drug candidates nitroxoline and nelfinavir as single agents or in combination with erlotinib in pancreatic cancer cells. <i>Journal of Experimental and Clinical Cancer Research</i> , 2018, 37, 236.	8.6	38
30	FPSE-HPLC-DAD method for the quantification of anticancer drugs in human whole blood, plasma, and urine. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2018, 1095, 204-213.	2.3	65
31	Long-term outcome of breast cancer patients with pathologic N3a lymph node stage. <i>Breast</i> , 2017, 32, 79-86.	2.2	12
32	Reply to Kadri Altundag: Do cut-off values of lymph node ratio and presence of perineural invasion affect survival in breast cancer patients with pathologic N3a lymph node stage?. <i>Breast</i> , 2017, 35, 218-219.	2.2	0
33	Intratumoral Delivery of Immunotherapy—Act Locally, Think Globally. <i>Journal of Immunology</i> , 2017, 198, 31-39.	0.8	171
34	Prognostic relevance of LGALS3BP in human colorectal carcinoma. <i>Journal of Translational Medicine</i> , 2015, 13, 248.	4.4	26
35	Effect of Targeted Agents on the Endocrine Response of Breast Cancer in the Neoadjuvant Setting: A Systematic Review. <i>Journal of Cancer</i> , 2015, 6, 575-582.	2.5	5
36	Identification of Subgroups of Early Breast Cancer Patients at High Risk of Nonadherence to Adjuvant Hormone Therapy: Results of an Italian Survey. <i>Clinical Breast Cancer</i> , 2015, 15, e131-e137.	2.4	27

#	ARTICLE	IF	CITATIONS
37	Outcomes of HER2-positive early breast cancer patients in the pre-trastuzumab and trastuzumab eras: a real-world multicenter observational analysis. The RETROHER study. <i>Breast Cancer Research and Treatment</i> , 2014, 147, 599-607.	2.5	39
38	Inhibition of Tumor Growth and Angiogenesis by SP-2, an Anti- α -Lectin, Galactoside-Binding Soluble 3 Binding Protein (LGALS3BP) Antibody. <i>Molecular Cancer Therapeutics</i> , 2014, 13, 916-925.	4.1	21
39	Long-Term Outcome of Neoadjuvant Endocrine Therapy with Aromatase Inhibitors in Elderly Women with Hormone Receptor-Positive Breast Cancer. <i>Annals of Surgical Oncology</i> , 2014, 21, 1575-1582.	1.5	11
40	Breast Cancer α -Tailored Follow-up α in Italian Oncology Units: A Web-Based Survey. <i>PLoS ONE</i> , 2014, 9, e94063.	2.5	8
41	Chemotherapy-induced nausea and vomiting in Italian cancer centers: results of CINVDAY, a prospective, multicenter study. <i>Tumori</i> , 2014, 100, e309-13.	1.1	1
42	Effectiveness of neoadjuvant trastuzumab and chemotherapy in HER2-overexpressing breast cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2013, 139, 1229-1240.	2.5	8
43	Breast cancer follow-up strategies in randomized phase III adjuvant clinical trials: a systematic review. <i>Journal of Experimental and Clinical Cancer Research</i> , 2013, 32, 89.	8.6	8
44	LGALS3BP, lectin galactoside-binding soluble 3 binding protein, induces vascular endothelial growth factor in human breast cancer cells and promotes angiogenesis. <i>Journal of Molecular Medicine</i> , 2013, 91, 83-94.	3.9	63
45	Long-term outcome of neoadjuvant systemic therapy for locally advanced breast cancer in routine clinical practice. <i>Journal of Cancer Research and Clinical Oncology</i> , 2013, 139, 269-280.	2.5	19
46	EV20, a Novel Anti-ErbB-3 Humanized Antibody, Promotes ErbB-3 Down-Regulation and Inhibits Tumor Growth In Vivo. <i>Translational Oncology</i> , 2013, 6, 676-IN9.	3.7	26
47	Tumor-derived microvesicles: The metastasomes. <i>Medical Hypotheses</i> , 2013, 80, 75-82.	1.5	21
48	Overexpression of activated phospholipase $\text{C}\hat{1}$ 31 is a risk factor for distant metastases in T1 α T2, N0 breast cancer patients undergoing adjuvant chemotherapy. <i>International Journal of Cancer</i> , 2013, 132, 1022-1031.	5.1	41
49	Circulating Autoantibodies to LGALS3BP: A Novel Biomarker for Cancer. <i>Disease Markers</i> , 2013, 35, 747-752.	1.3	6
50	An Epigenetic Approach to Pancreatic Cancer Treatment: The Prospective Role of Histone Deacetylase Inhibitors. <i>Current Cancer Drug Targets</i> , 2012, 12, 439-452.	1.6	29
51	Triplet Chemotherapy in Patients With Metastatic Colorectal Cancer: Toward the Best Way to Safely Administer a Highly Active Regimen in Clinical Practice. <i>Clinical Colorectal Cancer</i> , 2012, 11, 229-237.	2.3	18
52	Meta-analysis of phase III trials of docetaxel alone or in combination with chemotherapy in metastatic breast cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2012, 138, 221-229.	2.5	30
53	Fucans, but Not Fucomannoglucuronans, Determine the Biological Activities of Sulfated Polysaccharides from <i>Laminaria saccharina</i> Brown Seaweed. <i>PLoS ONE</i> , 2011, 6, e17283.	2.5	104
54	Strain- and Sex-Dependent Circadian Changes in Abcc2 Transporter Expression: Implications for Irinotecan Chronotolerance in Mouse Ileum. <i>PLoS ONE</i> , 2011, 6, e20393.	2.5	36

#	ARTICLE	IF	CITATIONS
55	Molecular mechanisms of endocrine resistance and their implication in the therapy of breast cancer. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2009, 1795, 62-81.	7.4	30
56	High expression of 90K (Mac-2 BP) is associated with poor survival in node-negative breast cancer patients not receiving adjuvant systemic therapies. <i>International Journal of Cancer</i> , 2009, 124, 333-338.	5.1	36
57	Timed-Flat Infusion of 5-Fluorouracil Associated with Docetaxel as First-Line Treatment of Patients with Metastatic Breast Cancer. <i>Breast Journal</i> , 2008, 14, 116-117.	1.0	0
58	Sunitinib malate (SU-11248) alone or in combination with low-dose docetaxel inhibits the growth of DU-145 prostate cancer xenografts. <i>Cancer Letters</i> , 2008, 270, 229-233.	7.2	44
59	Upstream Stimulatory Factor Regulates Constitutive Expression and Hormonal Suppression of the 90K (Mac-2BP) Protein. <i>Endocrinology</i> , 2007, 148, 3507-3517.	2.8	8
60	Relief of Symptoms After Gefitinib Is Associated With Improvement of Rest/Activity Rhythm in Advanced Lung Cancer. <i>Journal of Clinical Oncology</i> , 2007, 25, e17-e19.	1.6	19
61	A comparative study of the anti-inflammatory, anticoagulant, antiangiogenic, and antiadhesive activities of nine different fucoidans from brown seaweeds. <i>Glycobiology</i> , 2007, 17, 541-552.	2.5	844
62	A Stochastic Model for the HIV/AIDS Dynamic Evolution. <i>Mathematical Problems in Engineering</i> , 2007, 2007, 1-14.	1.1	8
63	Synthetic lactulose amines: novel class of anticancer agents that induce tumor-cell apoptosis and inhibit galectin-mediated homotypic cell aggregation and endothelial cell morphogenesis. <i>Glycobiology</i> , 2006, 16, 210-220.	2.5	114
64	Changes of Topoisomerase III α Expression in Breast Tumors after Neoadjuvant Chemotherapy Predicts Relapse-Free Survival. <i>Clinical Cancer Research</i> , 2006, 12, 1501-1506.	7.0	24
65	The 90K Protein Increases Major Histocompatibility Complex Class I Expression and Is Regulated by Hormones, β -Interferon, and Double-Strand Polynucleotides. <i>Endocrinology</i> , 2004, 145, 4728-4736.	2.8	23
66	Role of 90K protein in asthma and TH2-type cytokine expression. <i>Annals of Allergy, Asthma and Immunology</i> , 2004, 93, 485-492.	1.0	30
67	Lack of Expression of Galectin-3 Is Associated With a Poor Outcome in Node-Negative Patients With Laryngeal Squamous-Cell Carcinoma. <i>Journal of Clinical Oncology</i> , 2002, 20, 3850-3856.	1.6	42
68	Galectins and their ligands: amplifiers, silencers or tuners of the inflammatory response?. <i>Trends in Immunology</i> , 2002, 23, 313-320.	6.8	493
69	Expression of the 90K Tumor-Associated Protein in Benign and Malignant Melanocytic Lesions. <i>Journal of Investigative Dermatology</i> , 2002, 119, 187-190.	0.7	16
70	90K (Mac-2 BP) and galectins in tumor progression and metastasis. <i>Glycoconjugate Journal</i> , 2002, 19, 551-556.	2.7	148
71	Expression of 90K (Mac-2 BP) correlates with distant metastasis and predicts survival in stage I non-small cell lung cancer patients. <i>Cancer Research</i> , 2002, 62, 2535-9.	0.9	88
72	Glycoprotein 90K/MAC-2BP interacts with galectin-1 and mediates galectin-1-induced cell aggregation. <i>International Journal of Cancer</i> , 2001, 91, 167-172.	5.1	18

#	ARTICLE	IF	CITATIONS
73	Glycoprotein 90K/MAC-2BP interacts with galectin-1 and mediates galectin-1-induced cell aggregation. <i>International Journal of Cancer</i> , 2001, 91, 167-172.	5.1	95
74	Galectin-3 overexpression protects from apoptosis by improving cell adhesion properties. <i>International Journal of Cancer</i> , 2000, 85, 545-554.	5.1	194
75	Adhesion to 90K (Mac-2 BP) as a mechanism for lymphoma drug resistance in vivo. <i>Blood</i> , 2000, 96, 3282-3285.	1.4	39
76	Galectin-3 overexpression protects from cell damage and death by influencing mitochondrial homeostasis. <i>FEBS Letters</i> , 2000, 473, 311-315.	2.8	131
77	Identification of the Tumor Antigen 90K Domains Recognized by Monoclonal Antibodies SP2 and L3 and Preparation and Characterization of Novel Anti-90K Monoclonal Antibodies. <i>Biochemical and Biophysical Research Communications</i> , 1997, 232, 367-372.	2.1	16
78	Prognostic Value of a Novel Interferon-inducible 90K Tumor Antigen. <i>Annals of the New York Academy of Sciences</i> , 1996, 784, 288-293.	3.8	8
79	Elevated serum levels of 90K/MAC-2 BP predict unresponsiveness to α -interferon therapy in chronic HCV hepatitis patients. <i>Journal of Hepatology</i> , 1996, 25, 212-217.	3.7	88
80	The 90K Tumor-Associated Antigen and Clinical Progression in Human Immunodeficiency Virus Infection. <i>Journal of Acquired Immune Deficiency Syndromes</i> , 1995, 10, 450-456.	0.3	16
81	A 90-kDa Protein Serum Marker for the Prediction of Progression to AIDS in a Cohort of HIV-1+Homosexual Men. <i>AIDS Research and Human Retroviruses</i> , 1993, 9, 811-816.	1.1	31
82	DNA ploidy and S-phase fraction in pulmonary carcinoids. <i>European Journal of Cancer</i> , 1992, 28, 1933-1934.	2.8	2